Karl Hård
Investor Relations Contact bei EGETIS THERAPEUTICS AB
Profil
Karl J.
Hård is currently the VP, Head-Investor Relations & Communications at Egetis Therapeutics AB.
Previously, he worked as an Investor Relations Contact at AstraZeneca PLC and as an Assistant Professor at the University of Leiden.
He also served as the Head-Investor Relations & Corporate Communications at Redx Pharma Plc from 2016 to 2017 and as the Head-Investor Relations & Communications at Kiadis Pharma NV from 2017 to 2018.
Dr. Hård holds a doctorate degree from the University of Utrecht and a graduate degree from the University of Helsinki.
Aktive Positionen von Karl Hård
| Unternehmen | Position | Beginn |
|---|---|---|
| EGETIS THERAPEUTICS AB | Investor Relations Contact | 01.02.2022 |
Ehemalige bekannte Positionen von Karl Hård
| Unternehmen | Position | Ende |
|---|---|---|
| KIADIS PHARMA N.V. | Investor Relations Contact | 31.12.2018 |
| REDX PHARMA PLC | Investor Relations Contact | 02.07.2017 |
| University of Leiden | Corporate Officer/Principal | - |
| ASTRAZENECA PLC | Public Communications Contact | - |
Ausbildung von Karl Hård
| University of Utrecht | Doctorate Degree |
| University of Helsinki | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| EGETIS THERAPEUTICS AB | Health Technology |
| REDX PHARMA PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
